Scilex Holding Company Net Income (Loss) Attributable to Noncontrolling Interest
Scilex Holding Company (SCLX) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$1.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-14
- Scilex Holding Company net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$1.49M.
- Scilex Holding Company net income (loss) attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$1.74M.
- Scilex Holding Company net income (loss) attributable to noncontrolling interest for fiscal 2025 was $11.80M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|
| 2026-06-30 | -$1.49M 10-Q · filed 2026-08-14 | -$3.87M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $11.80M 10-K · filed 2026-04-10 | ||
| 2025-06-30 | -$1.74M 10-Q · filed 2026-08-14 | -$1.74M 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |